Related Experiment Video

Updated: Jul 20, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Classical and novel retinoids: their targets in cancer therapy

J A Fontana1, A K Rishi

  • 1John D Dingell VA Medical Center and the Department of Medicine and Karmanos Cancer Institute, Wayne State University Detroit, MI 48201, USA.

Leukemia
|April 18, 2002
PubMed

Insights

Novel retinoids, N-(4-hydroxyphenyl) retinamide (4-HPR) and CD437/AHPN, induce apoptosis in malignant cells. These retinoids show promise for treating premalignant and malignant conditions, though their precise mechanisms require further investigation.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Pharmacology

Background:

  • Retinoids regulate cellular growth and differentiation by interacting with nuclear receptors.
  • While effective in acute promyelocytic leukemia, retinoid therapeutic applications are limited.
  • Histone deacetylase inhibitors can enhance retinoid efficacy in certain cancers.

Purpose of the Study:

  • To investigate the apoptotic effects of novel retinoids, 4-HPR and CD437/AHPN, on various malignant cells.
  • To explore the potential mechanisms of action for these novel retinoids.
  • To assess the therapeutic potential of 4-HPR and CD437/AHPN in premalignant and malignant conditions.

Main Methods:

  • Treatment of malignant cell lines with 4-HPR and CD437/AHPN.
  • Induction of apoptosis assays.
  • Identification of potential molecular targets (details not specified in abstract).

Main Results:

  • 4-HPR and CD437/AHPN induced apoptosis across a broad spectrum of malignant cell types.
  • The precise molecular mechanisms underlying retinoid-induced apoptosis were not fully elucidated.
  • The involvement of retinoid receptors in the apoptosis induced by 4-HPR and CD437/AHPN remains uncertain.

Conclusions:

  • Novel retinoids 4-HPR and CD437/AHPN demonstrate significant potential for inducing apoptosis in diverse malignant cells.
  • These compounds represent promising therapeutic candidates for premalignant and malignant diseases.
  • Further research is needed to clarify the mechanisms of action and the role of retinoid receptors.

More Related Videos

Quantitative Analysis of Dietary Vitamin A Metabolites in Murine Ocular and Non-Ocular Tissues Using High-Performance Liquid Chromatography05:03

Quantitative Analysis of Dietary Vitamin A Metabolites in Murine Ocular and Non-Ocular Tissues Using High-Performance Liquid Chromatography

Published on: December 27, 2024

Methodology for Studying Interactions of Vitamin A Membrane Receptors and Opsin Protein with their Ligands in Generating the Retinylidene Protein08:18

Methodology for Studying Interactions of Vitamin A Membrane Receptors and Opsin Protein with their Ligands in Generating the Retinylidene Protein

Published on: October 4, 2024

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...